Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial

Abstract —Postmenopausal hormone replacement therapy (HRT) is associated with low cardiovascular morbidity and mortality in epidemiological studies. Yet, no randomized trial has examined whether HRT is effective for prevention of coronary heart disease (CHD) in women with increased risk. The objective of this study was to determine whether HRT can slow progression of atherosclerosis, measured as intima-media thickness (IMT) in carotid arteries. Carotid IMT is an appropriate intermediate end point to investigate clinically relevant effects on atherogenesis. This randomized, controlled, observer-blind, clinical, single-center trial enrolled 321 healthy postmenopausal women with increased IMT in ≥1 segment of the carotid arteries. For a period of 48 weeks, subjects received either 1 mg/d 17&bgr;-estradiol continuously plus 0.025 mg gestodene for 12 days every month (standard-progestin group), or 1 mg 17&bgr;-estradiol plus 0.025 mg gestodene for 12 days every third month (low-progestin group), or no HRT. Maximum IMT in 6 carotid artery segments (common, bifurcation, and internal, both sides) was measured by B-mode ultrasound before and after intervention. HRT did not slow IMT progression in carotid arteries. Mean maximum IMT in the carotid arteries increased by 0.02±0.05 mm in the no HRT group and by 0.03±0.05 and 0.03±0.05 mm, respectively, in the HRT groups (P >0.2). HRT significantly decreased LDL cholesterol, fibrinogen, and follicle-stimulating hormone. In conclusion, 1 year of HRT was not effective in slowing progression of subclinical atherosclerosis in postmenopausal women at increased risk.

[1]  J. Salonen,et al.  Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[2]  A. Algra,et al.  Reproducibility of in vivo carotid intima-media thickness measurements: a review. , 1997, Stroke.

[3]  R. Knopp,et al.  Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[4]  L. Mosekilde,et al.  Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. , 1998, Circulation.

[5]  B. Dawson-Saunders,et al.  Basic and Clinical Biostatistics , 1993 .

[6]  MD Anne-Marie Audet,et al.  Guidelines for Counseling Postmenopausal Women about Preventive Hormone Therapy , 1992, Annals of Internal Medicine.

[7]  V. Wynn,et al.  Comparison of transdermal and oral estrogen‐progestin replacement therapy: Effects on serum lipids and lipoproteins , 1992 .

[8]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[9]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[10]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[11]  M. Cortellaro,et al.  Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women , 1991 .

[12]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[13]  Kishore Shetty,et al.  Hormone replacement therapy , 2002, BMJ : British Medical Journal.

[14]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[15]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[16]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[17]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[18]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[19]  A. Keech,et al.  Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. , 1995, Circulation.

[20]  M. Anthony,et al.  Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. , 1996, British journal of obstetrics and gynaecology.

[21]  H. Helenius,et al.  Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT) , 1998, The Lancet.

[22]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[23]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[24]  E. Barrett-Connor,et al.  Hormone replacement therapy , 1998, BMJ.

[25]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[26]  E. Hemminki,et al.  A REVIEW OF POSTMENOPAUSAL HORMONE THERAPY RECOMMENDATIONS: POTENTIAL FOR SELECTION BIAS , 1993, Obstetrics and gynecology.

[27]  M. Cortellaro,et al.  Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. , 1991, Thrombosis research.

[28]  J. Edelstein,et al.  Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  A. Folsom,et al.  No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1996, Circulation.

[30]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[31]  M. Adams,et al.  Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[32]  R. Westendorp,et al.  Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? , 1994, BMJ.

[33]  P. Ganz,et al.  Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. , 1998, Circulation.

[34]  K. McPherson,et al.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.

[35]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[36]  D. Herrington.  The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. , 1999, Annals of internal medicine.

[37]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[38]  D. Herrington.  The HERS Trial Results: Paradigms Lost? , 1999, Annals of Internal Medicine.

[39]  A. Folsom,et al.  Variability in B-mode ultrasound measurements in the atherosclerosis risk in communities (ARIC) study. , 1996, Ultrasound in medicine & biology.

[40]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[41]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[42]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[43]  T. Waddell,et al.  Hormonal therapy increases arterial compliance in postmenopausal women. , 1997, Journal of the American College of Cardiology.

[44]  B. Rosner,et al.  Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. , 1992, The New England journal of medicine.

[45]  W. Mack,et al.  One‐Year Reduction and Longitudinal Analysis of Carotid Intima‐Media Thickness Associated With Colestipol/Niacin Therapy , 1993, Stroke.

[46]  M. Bond,et al.  Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. , 1995, Circulation.

[47]  R. Karas,et al.  The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.

[48]  C. Björkelund,et al.  Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden , 1999, BMJ.

[49]  I. Paakkari,et al.  Randomized Comparison of Oral and Transdermal Hormone Replacement on Carotid and Uterine Artery Resistance to Blood Flow , 1998, Obstetrics and gynecology.

[50]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[51]  C. Furberg,et al.  Estrogen Replacement Therapy and Progression of Intimal-Medial Thickness in the Carotid Arteries of Postmenopausal Women , 1995 .

[52]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[53]  C. Furberg,et al.  Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. , 1995, American journal of epidemiology.

[54]  H. Krumholz,et al.  Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. , 1997, Circulation.

[55]  S. Azen,et al.  Reduction in Carotid Arterial Wall Thickness Using Lovastatin and Dietary Therapy , 1996, Annals of Internal Medicine.

[56]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[57]  J. Toole,et al.  Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. , 1990, Circulation.

[58]  B. Perler,et al.  Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis: Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse III JR. Arterioscl Thromb 1991;11:1786–1794 , 1993 .

[59]  P. Poole‐Wilson,et al.  Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease , 1993, The Lancet.

[60]  P M Rautaharju,et al.  Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. , 1995, Stroke.

[61]  J. Toole,et al.  Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[62]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[63]  W. Mack,et al.  Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.